8. October 2019
Transglutaminase-Newsletter | October 2019
Dear valued customer,
Diagnostic and pharmaceutical industries are subject to increasing regulatory demands.
It is our pleasure to inform you that Zedira, provider of raw materials and services, complies with said requirements by the implementation of the management system as per
Zedira offers raw materials for diagnostics and API production:
Zedira’s Diagnostic Antigens
Assay substances and assays
Zedira’s Enzymes for diagnostics
Zedira ISO9001:2015 certification
Transglutaminase-Newsletter | October 2019Dear valued customer,
Diagnostic and pharmaceutical industries are subject to increasing regulatory demands.
It is our pleasure to inform you that Zedira, provider of raw materials and services, complies with said requirements by the implementation of the management system as per
DIN EN ISO 9001:2015
 | Evidence of conformity with the above standards was verified and is certified in accordance with "TÜV PROFiCERT" procedures. Certificate valid from 2019-09-13 Certificate registration No. 73 100 6469 Scope: Research, development, production, and distribution in the area of biotechnology. Download Certificate Z190913-english.pdf (English Version) Z190913-deutsch.pdf (German Version) |
Zedira offers raw materials for diagnostics and API production:
Microbial Transglutaminase –
Zedira’s tool for site specific conjugation in Antibody Drug Conjugate production
| Art. No. | Name | Unit | Price |
| T001 | Microbial (bacterial) transglutaminase (MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis) | 25 U 10x 25 U 20x 25 U | 270 € 2140 € 3750 € |
| T153 | Microbial (bacterial) transglutaminase Characterized for content of host cell protein (HCP), host cell DNA , endotoxin, and microbial burden | 25 U 10x 25 U 20x 25 U | 370 € 2950 € 5150 € |
| T178 | Microbial transglutaminase with C-terminal His6-Tag | 25 U 10x 25 U 20x 25 U | 370 € 2950 € 5150 € |
| Z009 | ZediXclusive Microbial Transglutaminase Assay Kit | 1 Kit | 310 € |
Zedira’s Diagnostic Antigens
| Art. No. | Name | Unit | Price |
| T122 | Recombinant TG2 (insect cells) Tissue transglutaminase Autoantigen in celiac disease | 250 µg | 370 € |
| T021 | Human neuronal transglutaminase (TG6, recombinantly produced in insect cells) Autoantigen in gluten ataxia | 250 µg | 475 € |
| T124 | Recombinant TG3 (insect cells) Epidermal transglutaminase Autoantigen in dermatitis herpetiformis | 200 µg | 370 € |
| G007 | DGPx1 (deamidated gliadin peptide) Antigen in celiac disease | 500 µg | 735 € |
| G006 | DGPx2 (Fusion protein of 2 deamidated gliadin peptides) Antigen in celiac disease | 500 µg | 735 € |
Assay substances and assays
| Art. No. | Name | Unit | Price |
| A101 | FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH | 10 mg | 520 € |
| F001 | FXIII-Assay Kit | 1 Kit | 575 € |
Zedira’s Enzymes for diagnostics
| Art. No. | Name | Unit | Price |
| P012 | Human Plasmin, recombinant Blood coagulation, plasmin inhibitor assay | 100 µg | 415 € |
| T070 | Human Factor XIIIa, activated Blood coagulation, TEM/TEG | 200 µg | 520 € |
Successful ISO9001:2015 recertification 
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation